It was great to see a bit of a rebound in the market, but I’m not sure we’re out of the woods yet. 10 of my companies are reporting next week, so I’m going to keep this post short and hopefully there will be a lot to talk about next week!
I made zero changes in April as I’m awaiting earnings and there wasn’t any significant enough news in my opinion to justify changes, especially since I re-balanced my portfolio. If anything, HIMS and NU would be on my list to add to with the Novo Nordisk announcement and the deterioration of the USD having some benefit to NU. Reddit is back on my radar but otherwise I have not had time to research many new companies lately.
Almost all of my companies were in the green in April except my biotechs, DCTH and KRYS who had been more resilient up to this point but haven’t been a beneficiary of the rotation back into tech growth. My tier 2 stocks NU and PAY saw the biggest rises, up over 20% in April, and HIMS was up 12%.
Some other news that caught my attention as potential catalysts:
- KRYS also got approval from the EU for VYJUVEK.
- NU was approved for a banking license in Mexico.
- NTRA announced that its Ultra-Sensitive Signatera test is now broadly available in the US.
And lastly, here is my results to date and current portfolio:
JAN: -1.54%
FEB: +2.77%
MAR: -14.77%
APR: +7.91%
YTD: -16.61%
(I think the huge off-hours drop from Jan 31 to Feb 1 is not reflected in the above monthly changes)
